Aquestive Therapeutics, Inc. (AQST): R&D Expense
$17.19M
Year ended 2025-12-31
$15.89M
Trailing 12 months to 2026-06-30
-0.6%
3-year compound annual growth
-2.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.19M | -15.2% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $20.28M | +54.8% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $13.10M | -25.0% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $17.48M | +2.5% | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | $17.05M | -14.3% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $19.89M | -3.3% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $20.57M | -11.0% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $23.11M | +4.4% | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $22.13M | n/a | 2019-03-14, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $17.19M | -15.2% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $5.57M | +15.6% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $97.58M | +49.4% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $159.29M | +15.3% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $182.78M | +14.5% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $3.72M | +78.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $61.12M | -27.7% |
Compare AQST, CPIX, XLO, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗